Waltham, Massachusetts-based Eloxx Pharmaceuticals announced changes in leadership and “organizational re-alignment” to focus on the company’s ELX-02 cystic fibrosis (CF) program.
As part of those changes, current chairman and chief executive officer Bob Ward, will be leaving the company. Ward held previous positions at AstraZeneca, Merck, Pfizer and Genentech. Gregory Williams will take on the role of chief executive officer. He was formerly chief operating officer. Neil Belloff, executive vice president, general counsel and corporate secretary, will act as chief operating officer. Tomer Kariv is taking on the position of board chairman. Kariv is the company’s chief medical officer.
